Humacyte HUMA
NASDAQ HUMA
$0.52 -0.01 (-1.89%)
At close: Sep 30, 2026 · 4:00 PM EDT

Humacyte (HUMA) Return on Equity [ROE] (2021 - 2026)

Updated

Humacyte (HUMA) reported Return on Equity [ROE] of -557.97% for Q2 2026, up 33.05 percentage points from -591.02% a year earlier and up 1100.27 percentage points from the prior quarter.

Analysis

Humacyte (HUMA) Return on Equity [ROE] (2021 - 2026) Analysis & Trends

For FY2023, Humacyte posted Return on Equity [ROE] of -155.09%, down 81.34 percentage points from FY2022.

  • By year, Return on Equity [ROE] came in at -73.75% in FY2022.
  • The Q2 2026 figure ranks as the highest quarterly Return on Equity [ROE] since Q1 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 25.32%
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 7.21%
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 84.40%
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 21.39%
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 83.75%
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -18.38%
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 4.97%
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 22.24%
10 Humacyte 144.46 Mn 144.46 Mn -825,000.00 -557.97%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -557.97%
Mar 31, 2026 -1,658.24%
Jun 30, 2025 -591.02%
Mar 31, 2024 -532.99%
Dec 31, 2023 -400.26%
Sep 30, 2023 -194.56%
Jun 30, 2023 -132.83%
Mar 31, 2023 -88.25%
Dec 31, 2022 -74.87%
Sep 30, 2022 -69.11%
Jun 30, 2022 -79.20%
Mar 31, 2022 -86.91%
Dec 31, 2021 -96.29%
API Access

Humacyte Return on Equity [ROE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=HUMA&period=max&api_key=YOUR_API_KEY